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Background
With TNF-blockers availability for spondyloarthritis
(SpA), evaluation of new drugs requires quick “go/no go”
signals in small scale, short term proof-of-concept (PoC)
trials. Biomarkers complementing clinical evaluations
may help reducing length and size of these PoCs. We
aimed to identify and validate serum biomarkers to pre-
dict clinical response at group level in these trials.
Methods
Matrix metalloproteinase-3 (MMP-3), Pentraxin-3 (PTX-
3), high sensitive C-reactive protein (hs-CRP), calprotectin,
Interleukin-6 (IL-6), Vascular Endothelial Growth Factor
(VEGF), and alpha-2-macroglobulin (alpha-2-MG) were
selected as biomarkers [1-3]. Serum levels were deter-
mined by ELISA in healthy controls (n=20) and at week 0
and 2 in SpA patients treated with infliximab (5 mg/kg;
week 0, 2, and 6) (n=18) or placebo (n=19). Patient and
physician global assessment of disease activity and BAS-
DAI were evaluated at week 0 and 12.
Results
Baseline serum levels of PTX-3, hs-CRP, calprotectin and
VEGF (all p<0.001) were increased in SpA compared to
healthy controls, whereas no differences were observed for
IL-6 and alpha-2-MG. Clinical evaluation at week 12
showed that infliximab but not placebo decreased disease
activity (p<0.005). Accordingly biomarker levels remained
stable in the placebo group. In contrast, a decrease of hs-
CRP (p<0.0001), calprotectin (p<0.001), and IL-6 (p =0.04)
was observed two weeks after infliximab initiation, with a
similar trend for MMP-3 (p=0.063). Other biomarker
levels were not significantly modulated. The Standardized
Response Mean (SRM), reflecting the predictive value at
the group level, was high for calprotectin (SRM=1.259)
and good for hs-CRP (SRM=0.746) and MMP-3
(SRM=0.521). At individual level, linear regression
revealed low correlations of changes in hs-CRP (r
2
between 0.24 and 0.36) and calprotectin (r
2 between 0.08
and 0.19) at week 2 with clinical outcome parameters at
week 12.
Conclusion
Early changes in serum calprotectin, hs-CRP, and MMP-3
showed a good ability to predict longer term clinical
response in SpA at group level. These biomarkers are cur-
rently being validated in independent PoC trials.
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